Qualigen Therapeutics Past Earnings Performance
Past criteria checks 0/6
Qualigen Therapeutics has been growing earnings at an average annual rate of 2.8%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 104.8% per year.
Key information
2.8%
Earnings growth rate
45.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -104.8% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Qualigen Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -9 | 4 | 0 |
| 31 Mar 24 | 0 | -11 | 6 | 0 |
| 31 Dec 23 | 0 | -12 | 6 | 0 |
| 30 Sep 23 | 0 | -14 | 8 | 0 |
| 30 Jun 23 | -2 | -12 | 8 | 0 |
| 31 Mar 23 | -1 | -13 | 9 | 0 |
| 31 Dec 22 | 0 | -14 | 10 | 0 |
| 30 Sep 22 | 1 | -15 | 11 | 0 |
| 30 Jun 22 | 5 | -16 | 12 | 0 |
| 31 Mar 22 | 4 | -17 | 12 | 0 |
| 31 Dec 21 | 6 | -18 | 12 | 0 |
| 30 Sep 21 | 5 | -7 | 12 | 0 |
| 30 Jun 21 | 5 | -12 | 11 | 0 |
| 31 Mar 21 | 5 | -25 | 10 | 0 |
| 31 Dec 20 | 4 | -20 | 8 | 0 |
| 30 Sep 20 | 5 | -28 | 6 | 0 |
| 30 Jun 20 | 5 | -20 | 4 | 0 |
| 31 Mar 20 | 6 | -2 | 2 | 0 |
| 31 Dec 19 | 5 | -1 | 1 | 0 |
| 31 Mar 19 | 6 | -1 | 1 | 0 |
| 31 Mar 18 | 10 | 0 | 2 | 0 |
Quality Earnings: 7R9 is currently unprofitable.
Growing Profit Margin: 7R9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7R9 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.
Accelerating Growth: Unable to compare 7R9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7R9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 7R9's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.